Multiple Myeloma: Update Bulletin #2

November 2017 | - | ID: M6FADC9CA44EN
FirstWord

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of top-line results of the Phase III A.R.R.O.W. trial for carfilzomib (Kyprolis) administered once-weekly at the 70 mg/m2 dose with dexamethasone in rrMM patients; FDA’s partial clinical hold suspending patient recruitment in three studies of BMS’ nivolumab (Opdivo)-based combinations in rrMM: CheckMate-602, CheckMate-039 and CA204142; and BioLineRx’s regulatory filings tolaunch the Phase III GENESIS trial for BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in MM patients

Business Questions:

• How do experts view Amgen’s top-line results for the Phase III A.R.R.O.W. trial?
• How do KOLs view the results for the higher dose carfilzomib (Kyprolis) and will it impact prescribing of bortezomib (Velcade) and ixazomib (Ninlaro)?
• What do experts say about potential increase in cardiovascular complications with the higher dose carfilzomib?
• How do experts view the clinical hold on CheckMate-602, CheckMate-039 and CA204142?
• Is there a future for PD-1/PD-L1-based combinations in multiple myeloma?
• What do experts expect from BioLineRx’s Phase III GENESIS trial for BL-8040?
• How do KOLs perceive BL-8040 potential for the mobilization of hematopoietic stem cells for autologous transplantation in patients?
• Could BL-8040 replace Sanofi’s plerixafor (Mozobil) and become the new standard of care?